KUALA LUMPUR, June 28 — CGS-CIMB Securities Sdn Bhd is positive on Pharmaniaga Bhd on the expectation of a decent financial year 2023-2024 earnings growth for the company.
“The ample excess production capacity at Pharmaniaga’s existing plants will allow it to ramp up output in the next three to five years — in light of rising pharmaceutical demand and new product launches — with little to no incremental capital expenditure, thus potentially leading to better economies of scale and margins,” it said.
United States United States Latest News, United States United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: staronline - 🏆 4. / 75 Read more »